ResearcherHospital de GaldakaoActive in the last 2 years

Daniel Oyón Lara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8648-3944; OpenAlex author ID A5084204554. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03268-5 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mariano Ponz‐Sarvisé · 1 shared paper, 2025 · strength 0.17
- Paper Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcin… DOI 10.1186/s13046-024-03268-5 ↗
Giulia Orsi · 1 shared paper, 2025 · strength 0.17
- Paper Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcin… DOI 10.1186/s13046-024-03268-5 ↗
Maite G. Fernández‐Barrena · 1 shared paper, 2025 · strength 0.17
- Paper Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcin… DOI 10.1186/s13046-024-03268-5 ↗
Silvestre Vicent Cambra · 1 shared paper, 2025 · strength 0.17
- Paper Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcin… DOI 10.1186/s13046-024-03268-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.